Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in active axial spondyloarthritis
NCT05785611Phase 3Active, not recruiting
- Sponsor
- Alfasigma
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in axial spondyloarthritis (axSpA) (2 arms), sponsored by Alfasigma. Primary endpoint: Assessment of SpondyloArthritis International Society 40% improvement at 16 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT05785611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785611.